Nvax Stock Quote and Company Information

Nvax stock is a publicly traded company, listed on the OTCQB Venture Market under the ticker symbol NVAX.

The company is focused on developing and commercializing novel therapeutics for the treatment of various diseases, including infectious diseases and cancer.

Nvax has a market capitalization of around $10 million, making it a small-cap stock.

The company's shares are thinly traded, with an average daily trading volume of less than 1 million shares.

For more insights, see: What Are Shares in Stocks

NVAX stock quote is a popular investment option, but before you dive in, let's take a closer look at the financial data.

The market capitalization of NVAX is over $10 billion, making it a significant player in the biotech industry. The stock has experienced significant growth, with a 5-year return of over 500%.

NVAX's revenue has been steadily increasing, with a 20% year-over-year growth rate. The company's strong financials are a major factor in its market capitalization.

The stock's price-to-earnings ratio is around 20, which is lower than the industry average. This could be an attractive feature for investors looking for value.

Readers also liked: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

NVAX's cash position is strong, with over $1 billion in cash reserves. This provides a safety net for the company in case of unexpected expenses or market downturns.

The company's debt-to-equity ratio is around 0.5, indicating a manageable level of debt. This suggests that NVAX is well-positioned to continue its growth trajectory.

Novavax, Inc. is a biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs.

The company is headquartered in Gaithersburg, Maryland, which is a hub for biotechnology and pharmaceutical companies.

NVAX stock has seen significant growth in recent years, with its market value increasing by over 50% in the past 12 months.

The company's vaccine development pipeline is a key driver of this growth, with multiple candidates in various stages of clinical trials.

NVAX stock has also been influenced by the COVID-19 pandemic, with the company's vaccine candidates being tested for their efficacy against the virus.

Investors are closely watching the company's progress in developing a vaccine against COVID-19, with many seeing it as a potential game-changer in the fight against the pandemic.

A different take: What Are Value Stocks vs Growth Stocks

Analyst opinions can be a valuable resource for investors, providing insights into a company's potential for growth and value. J.P. Morgan downgraded Novavax to Sell on July 30, 2024, with a price target of $8.

Bank of America Merrill Lynch has maintained a Hold rating for Novavax, with a price of $18 on June 14, 2024. This rating suggests a neutral outlook for the company.

H.C. Wainwright & Co. has maintained a Buy rating for Novavax, with a price of $19 on both May 13, 2024, and March 1, 2024. This rating indicates a positive outlook for the company's growth potential.

Here are the key analyst opinions for Novavax:

These analyst opinions provide a snapshot of the current market sentiment towards Novavax.

Novavax Inc's stock performance has been quite volatile over the years, with a 52 Week High of US$23.86 and a 52 Week Low of US$3.53.

The current share price is US$9.32, which is a significant drop from its high. However, it's still a 12.56% increase from a month ago.

Here's a breakdown of the company's price history:

The company's market value is substantial, with a market cap of $1,492,924,000.